CD8+ CTLs are directly capable of killing tumour cells and positively affect prognosis in a broad range of tumour types, including breast cancer, ovarian cancer, head and neck cancer and lung cancer [24–27]. The gene discussed is CD8A; the disease is head and neck cancer.